Company news
Rein Therapeutics, Inc. news in 2021
Rein Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
December 19, 2021
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 11, 2021
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
October 6, 2021
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
September 29, 2021
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
September 15, 2021
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
September 6, 2021
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
August 26, 2021
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 10, 2021
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
July 7, 2021
Aileron Therapeutics to be Added to the Russell Microcap® Index
June 23, 2021
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
May 18, 2021
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 23, 2021
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
March 3, 2021
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
March 1, 2021
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
January 10, 2021
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
January 5, 2021